2023 Update of the Japanese Heart Failure Society Scientific Statement on BNP and NT-proBNP Levels in Heart Failure Practice

6Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This revised 2023 statement on blood brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain (B-type) natriuretic peptide (NT-proBNP) represents an expert consensus that aims to enhance efficient referral from general practitioners or non-cardiovascular specialists, providing a comprehensive, up-to-date perspective on BNP and NT-proBNP in the diagnosis and management of heart failure, with a focus on the following two major modifications: (1) Changes regarding cutoff values for BNP and NT-proBNP (criteria for heart failure diagnosis and referral criteria to cardiovascular specialists); and (2) Content related to heart failure management using BNP and NT-proBNP (BNP-guided therapy).

Cite

CITATION STYLE

APA

MINAMISAWA, M., ANZAI, T., INOMATA, T., KINUGAWA, K., SAKATA, Y., SATO, N., … KUWAHARA, K. (2025, September 1). 2023 Update of the Japanese Heart Failure Society Scientific Statement on BNP and NT-proBNP Levels in Heart Failure Practice. Journal of Cardiac Failure. Elsevier B.V. https://doi.org/10.1016/j.cardfail.2025.03.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free